XNAS
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-07-30 | H1 2026 | — | 0.09 | — | $278.3M | — | -3.42% | +9.84% | +14.95% |
| 2026-03-05 | FY 2025 | 1.43 | 2.62 | +83.22% | $548.5M | ✅ Beat | -1.36% | +2.45% | +11.34% |
| 2025-08-07 |
| H1 2025 |
| — |
| 2.61 |
| — |
| $277.7M |
| — |
| -3.15% |
| -2.70% |
| -2.08% |
| 2025-03-19 | FY 2024 | — | 0.22 | — | $630.2M | — | -0.31% | -12.11% | -14.15% |
| 2024-07-31 | H1 2024 | — | 0.15 | — | $305.7M | — | -4.94% | +0.98% | -10.24% |
| 2024-02-28 | FY 2023 | — | 0.58 | — | $838.0M | — | — | — | — |
| 2023-07-31 | H1 2023 | — | 0.97 | — | $532.9M | — | +7.89% | -1.42% | +12.72% |
Showing last 7 quarters.